术前双膦酸盐治疗可能对肩关节置换术后的结局产生不利影响
这项单机构回顾性队列研究将29例术前三年内接受双膦酸盐治疗的患者与58例未暴露患者按性别、年龄、种族、民族、体质指数和置换类型进行匹配。术前双膦酸盐治疗与术中并发症(骨折;OR 39.40,95%CI 2.42至6305.70)和术后一年并发症(OR 7.83,95%CI 1.11至128.82)正相关,但术后两年并发症未达统计学显著(OR 3.45,95%CI 0.65至25.28)。作者结论认为术前三年内接受双膦酸盐治疗的患者术中及术后一年并发症风险更高。
要点
- 术前三年内双膦酸盐暴露与肩关节置换术中骨折风险正相关(OR 39.40,95%CI 2.42至6305.70)。
- 术前双膦酸盐暴露与术后一年并发症风险正相关(OR 7.83,95%CI 1.11至128.82)。
- 术后两年并发症未达统计学显著(OR 3.45,95%CI 0.65至25.28),术后一年并发症检验效能为63%。
核心结论
- 作者结论认为,肩关节置换术前三年内接受双膦酸盐治疗的患者与未接受该治疗者相比,术中及术后一年并发症风险更高。
研究设计与样本
- 单机构回顾性队列研究,将每例术前接受双膦酸盐治疗的患者按性别、年龄、种族、民族、体质指数和置换类型匹配两例未暴露患者。
- 共纳入87例患者:双膦酸盐暴露组(BP+)29例,非暴露组(BP-)58例。
- BP+组26例女性、3例男性,平均年龄71.4岁(范围51至87岁);BP-组52例女性、6例男性,平均年龄72.1岁(范围53至88岁)。
- 术前双膦酸盐治疗定义为肩关节置换术前三年期间接受的治疗。
- 主要结局指标为术中并发症及术后一年和两年并发症的发生率。
主要发现
- 术前双膦酸盐治疗与术中并发症(骨折)正相关(OR 39.40,95%CI 2.42至6305.70)。
- 术前双膦酸盐治疗与术后一年并发症正相关(OR 7.83,95%CI 1.11至128.82)。
- 术后两年并发症未达统计学显著(OR 3.45,95%CI 0.65至25.28)。
- 术后一年并发症的检验效能为63%。
局限性
- 术后一年并发症的检验效能为63%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to investigate the effects of preoperative bisphosphonate treatment on the intra- and postoperative outcomes of arthroplasty of the shoulder. The hypothesis was that previous bisphosphonate treatment would adversely affect both intra- and postoperative outcomes. PATIENTS AND METHODS: A retrospective cohort study was conducted involving patients undergoing arthroplasty of the shoulder, at a single institution. Two patients with no previous bisphosphonate treatment were matched to each patient who had received this treatment preoperatively by gender, age, race, ethnicity, body mass index (BMI), and type of arthroplasty. Previous bisphosphonate treatment was defined as treatment occurring during the three-year period before the arthroplasty. The primary outcome measure was the incidence of intraoperative complications and those occurring at one and two years postoperatively. A total of 87 patients were included: 29 in the bisphosphonates-exposed (BP+) group and 58 in the non-exposed (BP-) group. In the BP+ group, there were 26 female and three male patients, with a mean age of 71.4 years (51 to 87). In the BP- group, there were 52 female and six male patients, with a mean age of 72.1 years (53 to 88). RESULTS: Previous treatment with bisphosphonates was positively associated with intraoperative complications (fracture; odds ratio (OR) 39.40, 95% confidence interval (CI) 2.42 to 6305.70) and one-year postoperative complications (OR 7.83, 95% CI 1.11 to 128.82), but did not achieve statistical significance for complications two years postoperatively (OR 3.45, 95% CI 0.65 to 25.28). The power was 63% for complications at one year. CONCLUSION: Patients who are treated with bisphosphonates during the three-year period before shoulder arthroplasty have a greater risk of intraoperative and one-year postoperative complications compared with those without this previous treatment.
引用
- Mai DH, Oh C, Doany ME, et al. Preoperative bisphosphonate treatment may adversely affect the outcome after shoulder arthroplasty. Bone Joint J. 2019. PMID: 30700113. doi:10.1302/0301-620X.101B2.BJJ-2018-0906.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。